For millions of people with dangerously high cholesterol, treatment could soon change fundamentally. Enlicitide, an oral drug that blocks the PCSK9 protein, lowers LDL cholesterol by nearly 56 percentage points more than placebo, delivering a level of protection previously achievable only through injections. The Phase 3 results were published in February 2026 in the New England Journal of Medicine and have been widely described by cardiologists as a breakthrough.
Why LDL Is So Dangerous
LDL cholesterol accumulates in the walls of blood vessels, narrowing them and greatly increasing the risk of heart attack and stroke. According to the World Health Organization, cardiovascular diseases kill approximately 17.9 million people per year worldwide, and elevated LDL is considered one of the most important modifiable risk factors. Statins, the most commonly prescribed drug class for LDL reduction, help many patients but are not effective for everyone and cause severe side effects such as muscle pain in some people.
As an alternative, PCSK9 inhibitors came onto the market several years ago. The PCSK9 protein slows the body's own removal of LDL from the blood. Blocking it allows more LDL to be cleared from the bloodstream. The existing PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), are highly effective but must be injected under the skin every two weeks. For many patients, that is a significant barrier.
What the CORALreef Trial Shows
The trial enrolled 2,909 adults at high cardiovascular risk across 14 countries who still had elevated LDL levels despite statin therapy. Half received enlicitide; half received placebo, each for 24 weeks. Enlicitide reduced LDL by an average of 55.8 percentage points compared to the placebo group, corresponding to roughly a 57 percent reduction from the treatment group's baseline values.
Additional cardiovascular markers improved significantly:
- Non-HDL cholesterol fell by 53 percent.
- Apolipoprotein B (ApoB), a direct marker of atherosclerotic risk, fell by 50 percent.
- Lipoprotein(a), a genetically determined risk factor, fell by 28 percent.
The lipoprotein(a) reduction is particularly notable because this marker has until now been largely untreatable. Cardiologists regard a reduction of nearly one third alongside LDL lowering as remarkable.
First Pill to Replace Injections
The key difference from existing PCSK9 inhibitors is that enlicitide is a tablet. That sounds straightforward, but the practical advantage is substantial. Injectable drugs require either regular clinic visits or trained patients who can self-administer. Many people, especially older patients or those with limited mobility, take injectable therapies irregularly or not at all. A daily tablet has a significantly better chance of being taken consistently.
Enlicitide is being developed by Merck (known outside the United States as MSD). The drug is still in the regulatory approval process. If the FDA and EMA approve it, it could reach the market within a few years.
Who Benefits?
The trial focused on patients for whom statins alone are insufficient: people with familial hypercholesterolaemia, a genetic condition affecting an estimated 30 million people worldwide, and patients following a heart attack or stroke who still have elevated LDL despite drug therapy. This group has until now been dependent on expensive injectable PCSK9 inhibitors.
What Still Needs to Be Shown
The trial measures biomarkers, not heart attacks. It shows that enlicitide lowers LDL, but not yet whether that translates into reduced mortality. A long-term cardiovascular outcomes study is planned and will be necessary before health authorities issue broad recommendations. Long-term safety data beyond two years is also lacking, the standard caveat for any new drug.
The European Society of Cardiology is expected to discuss the trial at its annual congress in Rotterdam in August 2026. European regulatory approval is not anticipated before 2028 at the earliest.